Anika Therapeutics appoints new CFO

Anika Therapeutics, Inc., a developer of therapeutic products for tissue protection, healing and repair, has appointed Sylvia Cheung as the company's CFO.

Cheung takes charges as the company's CFO, effective April 1, 2013. Cheung, who has served as Anika's vice president for strategic processes since February 2012, will succeed Kevin W. Quinlan.

Prior to her current position as vice president of strategic processes, Cheung served as General Manager for the company's Italy-based subsidiary, Anika Srl. She joined Anika as Controller in 2005. In addition to fulfilling wide-ranging financial responsibilities as Controller, Cheung led the company's integration of Anika Srl subsequent to its acquisition in 2009. Prior to Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc.

"Serving as our new CFO will enable Sylvia to apply her financial acumen and business experience not only in leading Anika's finance team, but in playing a key role in our efforts to strategically position the company for growth," said Charles H. Sherwood, Ph.D., Anika's President and CEO. "Sylvia has the ideal combination of talents, skills and experience as well as a record of success as a member of Anika's senior management team to ensure continuity in the CFO position and help advance our company into the future."

"On behalf of the board of directors, I extend our thanks to Kevin Quinlan for his years of dedicated service with Anika," Sherwood said. "We look forward to Kevin's continued contributions during the transition process in the weeks ahead, and wish him success in his future endeavors."